The global ACL/PCL reconstruction market was valued at approximately $1.3 billion in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 6.0%, reaching over $2 billion by 2032.
This report covers allografts and fixation devices used in ACL and PCL reconstruction procedures. Allografts are segmented by type into bone-patella tendon bone (BTB), non-sutured soft tissue, and pre-sutured soft tissues. Fixation devices are segmented by type into interference screws, cortical fixation, intratunnel fixation, washer and post, and cross-pins. The report quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
Advanced fixation technologies continued to drive market development in 2025. Adjustable loop cortical fixation devices allow surgeons to match graft tensioning to patient-specific tunnel length and diameter intraoperatively, preserving graft integrity and expanding the range of viable graft options. Non-sutured soft tissue allografts remained a cost-effective alternative to BTB allografts, particularly in outpatient settings prioritizing procedural efficiency.
The sports industry remains a key commercial driver, with manufacturers maintaining partnerships with professional sports organizations that fund research and development, clinical trials, and surgical training programs. These collaborations accelerate the adoption of next-generation fixation devices and expand the clinical evidence base for improved anatomic reconstruction techniques.
Fixation technology has evolved considerably over the past decade. Adjustable loop cortical suspension devices are gaining market share over interference screws due to their intraoperative tensioning flexibility, ease of deployment, and reliable cortical fixation strength. The ability to fine-tune loop length to match patient-specific tunnel geometry reduces the need to resize grafts and preserves biomechanical integrity, which is particularly valuable in anatomic reconstructions where graft diameter is a key determinant of stability and retear risk. Biocomposite and PEEK interference screws remain widely used in intratunnel and bone-to-bone fixation, and open architecture designs that support bone ingrowth are gaining traction within this format.
The graft landscape reflects a balance between allograft accessibility and autograft performance. Autografts offer superior biological compatibility and lower failure rates in active populations, but allografts provide procedural efficiency and are preferred in certain patient demographics and outpatient settings. Supply constraints for donor tissue limit allograft market growth, as demand for specific donor tendons consistently outpaces available supply and processing capacity. Non-sutured and preconstructed soft tissue allografts remain a cost-effective alternative to BTB constructs in settings that prioritize streamlined workflows.
A substantial majority of ACL and PCL reconstruction procedures are performed in ambulatory surgery centers or other outpatient settings. These facilities prioritize efficient, cost-effective arthroscopic techniques and operate with tighter overhead and lower reimbursement rates than hospitals, placing consistent downward pressure on device pricing. This environment influences product selection and design priorities, favoring systems that support procedural efficiency while maintaining clinical performance.
Smith and Nephew remained the second leading competitor in the total ACL/PCL reconstruction market in 2025. The company led the cortical fixation segment with the ULTRABUTTON adjustable fixation family, including the ULTRABUTTON QUAD and ULTRABUTTON BB for diverse graft types, frequently paired with the QUADTRAC Quadriceps Tendon Harvest Guide System to streamline workflows. Smith and Nephew was also a leading competitor in the interference screw category with its BIOSURE screws in PEEK and biocomposite materials. The BIOSURE REGENESORB interference screw gained significant traction during the year due to its open architecture design that supports natural bone ingrowth.
DePuy Synthes remained the third leading company in 2025. Its market position was anchored by leadership in intratunnel fixation through the INTRAFIX ADVANCE Tibial Fastener System, which provides 360-degree graft-to-bone compression. The RIGIDFIX Curve Cross Pin System addresses anatomic femoral fixation, and the MILAGRO ADVANCE Interference Screw in BIOCRYL RAPIDE biocomposite supports bony ingrowth at the repair site. The RIGIDLOOP family was expanded to include the RIGIDLOOP Adjustable Cortical System and RIGIDLOOP BTB Adjustable Cortical System for precise tensioning across both soft tissue and bone-to-bone graft constructs.
6 charts and 61 figures illustrating market segmentation and performance metrics.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
This report covers allografts and fixation devices used in ACL and PCL reconstruction procedures. Allografts are segmented by type into bone-patella tendon bone (BTB), non-sutured soft tissue, and pre-sutured soft tissues. Fixation devices are segmented by type into interference screws, cortical fixation, intratunnel fixation, washer and post, and cross-pins. The report quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
Advanced fixation technologies continued to drive market development in 2025. Adjustable loop cortical fixation devices allow surgeons to match graft tensioning to patient-specific tunnel length and diameter intraoperatively, preserving graft integrity and expanding the range of viable graft options. Non-sutured soft tissue allografts remained a cost-effective alternative to BTB allografts, particularly in outpatient settings prioritizing procedural efficiency.
The sports industry remains a key commercial driver, with manufacturers maintaining partnerships with professional sports organizations that fund research and development, clinical trials, and surgical training programs. These collaborations accelerate the adoption of next-generation fixation devices and expand the clinical evidence base for improved anatomic reconstruction techniques.
Market Overview
The global ACL/PCL reconstruction market is one of the most active segments within orthopedic sports medicine, supported by a high volume of ligament injuries across athletic and active populations and a growing emphasis on anatomic precision and biological integration in reconstruction technique. The market encompasses both the graft products used to replace damaged ligaments and the fixation devices that secure those grafts within bone tunnels, with product innovation concentrated across both categories.Fixation technology has evolved considerably over the past decade. Adjustable loop cortical suspension devices are gaining market share over interference screws due to their intraoperative tensioning flexibility, ease of deployment, and reliable cortical fixation strength. The ability to fine-tune loop length to match patient-specific tunnel geometry reduces the need to resize grafts and preserves biomechanical integrity, which is particularly valuable in anatomic reconstructions where graft diameter is a key determinant of stability and retear risk. Biocomposite and PEEK interference screws remain widely used in intratunnel and bone-to-bone fixation, and open architecture designs that support bone ingrowth are gaining traction within this format.
The graft landscape reflects a balance between allograft accessibility and autograft performance. Autografts offer superior biological compatibility and lower failure rates in active populations, but allografts provide procedural efficiency and are preferred in certain patient demographics and outpatient settings. Supply constraints for donor tissue limit allograft market growth, as demand for specific donor tendons consistently outpaces available supply and processing capacity. Non-sutured and preconstructed soft tissue allografts remain a cost-effective alternative to BTB constructs in settings that prioritize streamlined workflows.
A substantial majority of ACL and PCL reconstruction procedures are performed in ambulatory surgery centers or other outpatient settings. These facilities prioritize efficient, cost-effective arthroscopic techniques and operate with tighter overhead and lower reimbursement rates than hospitals, placing consistent downward pressure on device pricing. This environment influences product selection and design priorities, favoring systems that support procedural efficiency while maintaining clinical performance.
Market Drivers
Sports Industry
Manufacturers in the ACL/PCL reconstruction market maintain close collaborations with professional sports organizations to ensure that treatment options remain clinically current and optimized for high-performance patients. These partnerships provide financial backing for research and development, clinical trials, and longitudinal outcome studies that support the evidence base for new fixation approaches and graft protocols. They also fund specialized surgical fellowships and educational programs that improve reconstruction technique across clinical settings. Smith and Nephew's multiyear partnership with the UFC is a recent example of this model in practice. By exposing high-volume surgeons to new products in performance-focused contexts, these collaborations accelerate clinical adoption and support sustained investment in next-generation reconstruction technologies.Advanced Fixation Options
Improved fixation technologies continue to expand graft versatility and support higher-quality anatomic reconstructions across both ACL and PCL indications. Adjustable loop cortical suspension devices allow intraoperative tensioning matched to patient-specific tunnel length and graft diameter, reducing the need to resize soft tissue allografts and preserving graft integrity throughout the procedure. The ongoing shift toward these systems reflects the clinical value placed on precise tension control and reproducibility in anatomic tunnel positioning. Intratunnel and interference screw formats also demonstrate sustained utilization, with biocomposite and PEEK platforms continuing to grow as surgeons tailor fixation strategy to graft type and anatomy. Because next-generation fixation platforms generally carry higher ASPs, continued procedural migration toward adjustable cortical systems and biologically integrated implants is expected to support overall market value expansion through the forecast period.Market Limiters
Limited Supply of Allograft
Rising demand for donor tendons continues to outpace the supply of available allografts. The availability of specific donor tendons is never fully guaranteed, and allograft use is constrained by the complexity of tissue processing and specific limitations on donor age and graft dimensions that vary across patient populations. Although safety standards and sterilization techniques have improved significantly, a residual risk of disease transmission or tissue rejection remains compared to autograft material. Because autografts offer superior biological compatibility and lower failure rates in active patients, allograft market growth will remain constrained over the forecast period by both supply-side limitations and the clinical preference for autologous tissue among younger and higher-demand patient populations.Outpatient Setting and ASC Pricing Pressure
A substantial majority of ACL and PCL reconstruction procedures worldwide are performed in ambulatory surgery centers or other outpatient settings. These facilities operate with significantly tighter overhead and lower reimbursement rates than traditional hospitals and prioritize efficient, cost-effective arthroscopic techniques to maintain profitability. This environment exerts sustained downward pressure on device pricing, limiting price growth across both fixation device and allograft categories. Product selection in these settings often favors established, cost-competitive options over premium alternatives, which constrains the pace of ASP improvement and limits the commercial upside of higher-priced next-generation implants in high-volume outpatient accounts.Market Coverage and Data Scope
- Quantitative coverage: Procedure numbers, market size, market shares, market forecasts, growth rates, units sold, and average selling prices.
- Qualitative coverage: Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, and practice trends shaping demand.
- Time frame: Base year 2025, forecasts 2026 to 2032, historical data 2022 to 2024.
- Data sources: Primary interviews with orthopedic industry leaders and sports medicine surgeons, regulatory data, hospital and ASC procurement data, import and export data, and the iData Research internal database.
- Care settings: Hospitals, ambulatory surgery centers, and orthopedic specialty clinics.
Markets Covered and Segmentation
ACL/PCL Reconstruction Allograft Market
- Type: Bone-Patella Tendon Bone (BTB), Non-Sutured Soft Tissue, and Pre-Sutured Soft Tissues
ACL/PCL Reconstruction Fixation Device Market
- Type: Interference Screw, Cortical Fixation, Intratunnel Fixation, Washer and Post, and Cross-Pins
Competitive Analysis
Arthrex led the combined ACL/PCL reconstruction market in 2025 and maintained dominance across every global region. The company's leadership in the fixation device market was driven by the BioComposite interference screw line and the TightRope II adjustable loop system, which allows for precise intraoperative graft tensioning. Arthrex also promoted the InternalBrace technique to provide supplemental support for the healing ligament and the FiberTag TightRope II specifically for quadriceps tendon graft applications. The company also emphasized the QuadPro tendon harvester and FiberRing suture during 2025 to improve procedural efficiency and graft preparation for anatomic reconstructions.Smith and Nephew remained the second leading competitor in the total ACL/PCL reconstruction market in 2025. The company led the cortical fixation segment with the ULTRABUTTON adjustable fixation family, including the ULTRABUTTON QUAD and ULTRABUTTON BB for diverse graft types, frequently paired with the QUADTRAC Quadriceps Tendon Harvest Guide System to streamline workflows. Smith and Nephew was also a leading competitor in the interference screw category with its BIOSURE screws in PEEK and biocomposite materials. The BIOSURE REGENESORB interference screw gained significant traction during the year due to its open architecture design that supports natural bone ingrowth.
DePuy Synthes remained the third leading company in 2025. Its market position was anchored by leadership in intratunnel fixation through the INTRAFIX ADVANCE Tibial Fastener System, which provides 360-degree graft-to-bone compression. The RIGIDFIX Curve Cross Pin System addresses anatomic femoral fixation, and the MILAGRO ADVANCE Interference Screw in BIOCRYL RAPIDE biocomposite supports bony ingrowth at the repair site. The RIGIDLOOP family was expanded to include the RIGIDLOOP Adjustable Cortical System and RIGIDLOOP BTB Adjustable Cortical System for precise tensioning across both soft tissue and bone-to-bone graft constructs.
Technology and Practice Trends
- Adjustable loop cortical fixation gaining share: Cortical suspension devices with intraoperative loop adjustment are displacing interference screws in many reconstruction applications, offering tensioning precision and deployment simplicity.
- Quadriceps tendon graft adoption: Growing clinical interest in quadriceps tendon grafts is driving demand for specialized harvesting guides and fixation systems designed for this graft construct.
- Biocomposite and PEEK interference screws: Biologically integrated screw materials continue to displace metal options, with open architecture designs supporting bone ingrowth gaining meaningful clinical traction.
- Anatomic reconstruction techniques: Advances in tunnel positioning and fixation reproducibility are supporting more consistent anatomic ligament placement and improving long-term stability outcomes.
- Supplemental ligament support: Adoption of supplemental constructs such as the InternalBrace technique is growing for cases where additional healing ligament support is a clinical priority.
- Non-sutured and preconstructed allografts: Cost-effective soft tissue allograft formats designed for procedural efficiency continue to expand access to allograft reconstruction in outpatient settings.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.Deliverables
68 pages of detailed narrative analysis, tables, and figures.6 charts and 61 figures illustrating market segmentation and performance metrics.
Methodology Appendix, Abbreviation and Acronym Glossary explaining all data definitions and modeling assumptions.
Licensing options: single-user, site, and enterprise.
Why This Report
- Where are the largest and fastest-growing opportunities within the global ACL/PCL reconstruction market through 2032?
- How are adjustable loop cortical fixation devices reshaping fixation strategy, graft selection, and ASP growth across the fixation device market?
- What is the commercial impact of sports industry partnerships on R&D investment, clinical evidence generation, and surgeon education programs?
- How are allograft supply constraints shaping the balance between allograft and autograft use across global markets and patient populations?
- What role are outpatient settings and ASC pricing dynamics playing in limiting device price growth and constraining premium product adoption?
- Which companies lead each product segment and what are their core platforms, recent expansions, and strategic priorities?
- How are quadriceps tendon grafts and compatible harvesting systems influencing product development investment across the market?
- What are the key risks to growth, including allograft supply limitations, ASC pricing pressure, and reimbursement variability across global regions?
Table of Contents
Research Methodology
ACL/PCL Reconstruction Market
List of Charts
List of Figures
